Primary systemic therapy for operable breast cancer.
Identifieur interne : 001B48 ( Pmc/Curation ); précédent : 001B47; suivant : 001B49Primary systemic therapy for operable breast cancer.
Auteurs : E. D. Anderson ; A. P. Forrest ; R. A. Hawkins ; T. J. Anderson ; R. C. Leonard ; U. ChettySource :
- British Journal of Cancer [ 0007-0920 ] ; 1991.
Abstract
Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) have received primary systemic therapy. Response was assessed following 12 weeks of systemic therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastectomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months). Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours with an oestrogen receptor (ER) concentration of greater than or equal to 20 fmol mb-1 cytosol protein. Cytotoxic therapy was reserved for patients with tumours of ER concentration less than 20 fmol mg-1 cytosol protein (n = 27) or when endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy outlined in this paper should now be tested against orthodox management by controlled randomised trial.
Url:
PubMed: 1827031
PubMed Central: 1972365
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B49
Links to Exploration step
PMC:1972365Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Primary systemic therapy for operable breast cancer.</title><author><name sortKey="Anderson, E D" sort="Anderson, E D" uniqKey="Anderson E" first="E. D." last="Anderson">E. D. Anderson</name></author><author><name sortKey="Forrest, A P" sort="Forrest, A P" uniqKey="Forrest A" first="A. P." last="Forrest">A. P. Forrest</name></author><author><name sortKey="Hawkins, R A" sort="Hawkins, R A" uniqKey="Hawkins R" first="R. A." last="Hawkins">R. A. Hawkins</name></author><author><name sortKey="Anderson, T J" sort="Anderson, T J" uniqKey="Anderson T" first="T. J." last="Anderson">T. J. Anderson</name></author><author><name sortKey="Leonard, R C" sort="Leonard, R C" uniqKey="Leonard R" first="R. C." last="Leonard">R. C. Leonard</name></author><author><name sortKey="Chetty, U" sort="Chetty, U" uniqKey="Chetty U" first="U." last="Chetty">U. Chetty</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">1827031</idno><idno type="pmc">1972365</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972365</idno><idno type="RBID">PMC:1972365</idno><date when="1991">1991</date><idno type="wicri:Area/Pmc/Corpus">001B49</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001B49</idno><idno type="wicri:Area/Pmc/Curation">001B48</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001B48</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Primary systemic therapy for operable breast cancer.</title><author><name sortKey="Anderson, E D" sort="Anderson, E D" uniqKey="Anderson E" first="E. D." last="Anderson">E. D. Anderson</name></author><author><name sortKey="Forrest, A P" sort="Forrest, A P" uniqKey="Forrest A" first="A. P." last="Forrest">A. P. Forrest</name></author><author><name sortKey="Hawkins, R A" sort="Hawkins, R A" uniqKey="Hawkins R" first="R. A." last="Hawkins">R. A. Hawkins</name></author><author><name sortKey="Anderson, T J" sort="Anderson, T J" uniqKey="Anderson T" first="T. J." last="Anderson">T. J. Anderson</name></author><author><name sortKey="Leonard, R C" sort="Leonard, R C" uniqKey="Leonard R" first="R. C." last="Leonard">R. C. Leonard</name></author><author><name sortKey="Chetty, U" sort="Chetty, U" uniqKey="Chetty U" first="U." last="Chetty">U. Chetty</name></author></analytic><series><title level="j">British Journal of Cancer</title><idno type="ISSN">0007-0920</idno><idno type="eISSN">1532-1827</idno><imprint><date when="1991">1991</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) have received primary systemic therapy. Response was assessed following 12 weeks of systemic therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastectomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months). Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours with an oestrogen receptor (ER) concentration of greater than or equal to 20 fmol mb-1 cytosol protein. Cytotoxic therapy was reserved for patients with tumours of ER concentration less than 20 fmol mg-1 cytosol protein (n = 27) or when endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy outlined in this paper should now be tested against orthodox management by controlled randomised trial.</p></div></front></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">1827031</article-id><article-id pub-id-type="pmc">1972365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Primary systemic therapy for operable breast cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>E. D.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Forrest</surname><given-names>A. P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hawkins</surname><given-names>R. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>T. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Leonard</surname><given-names>R. C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chetty</surname><given-names>U.</given-names></name></contrib></contrib-group><aff>University Department of Surgery, Royal Infirmary, Edinburgh, UK.</aff><pub-date pub-type="ppub"><month>4</month><year>1991</year></pub-date><volume>63</volume><issue>4</issue><fpage>561</fpage><lpage>566</lpage><abstract><p>Eighty-eight patients presenting with operable breast cancer of 4 cm or greater in diameter (T2, T3, N0, N1, M0) have received primary systemic therapy. Response was assessed following 12 weeks of systemic therapy by linear regression analysis of changes in tumour volume. Definitive locoregional surgery (mastectomy n = 82, wide local excision n = 6) was performed on completion of systemic therapy (3-6 months). Response was observed in 24 (39%) of the 61 patients who received endocrine therapy; all 24 had tumours with an oestrogen receptor (ER) concentration of greater than or equal to 20 fmol mb-1 cytosol protein. Cytotoxic therapy was reserved for patients with tumours of ER concentration less than 20 fmol mg-1 cytosol protein (n = 27) or when endocrine therapy had failed (n = 20). Response was observed in 34 patients (72%). The overall survival rate at 3 years was 86%, with 81% remaining free from local relapse. We propose that the treatment policy outlined in this paper should now be tested against orthodox management by controlled randomised trial.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B48 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001B48 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1972365
|texte= Primary systemic therapy for operable breast cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:1827031" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |